Incretin Atlas › Trials › HRS9531-301 (GEMINI-1, NCT06396429)
HRS9531-301 (GEMINI-1, NCT06396429)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Official title
- To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2024-05 → 2025-07
- Participants
- 567
- Duration
- 48 weeks
- Registry
- NCT06396429
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 mg | obesity china | 48 | 567 | −11.2 % vs −1.4 % Δ −9.8 pp | −10.7 % vs −1.4 % Δ −9.3 pp | — | 0.7 vs 0.0 | — | 16.2 vs 4.9 | 14.1 vs 2.1 | 1.4 vs 5.6 | — | press release |
| 4 mg | obesity china | 48 | 567 | −17.4 % vs −1.4 % Δ −16.0 pp | −16.4 % vs −1.4 % Δ −15.0 pp | — | 0.7 vs 0.0 | — | 17.0 vs 4.9 | 19.1 vs 2.1 | 5.0 vs 5.6 | — | press release |
| 6 mg | obesity china | 48 | 567 | −19.2 % vs −1.4 % Δ −17.8 pp | −17.7 % vs −1.4 % Δ −16.3 pp | — | 1.4 vs 0.0 | — | 27.0 vs 4.9 | 24.1 vs 2.1 | 4.3 vs 5.6 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (18)
- 2 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 2 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 2 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 2 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 2 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 2 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
- 4 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 4 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 4 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 4 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 4 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 4 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
- 6 mg · weight_tp · press release
Based on the treatment policy estimand^II, participants taking HRS9531 achieved a mean weight loss of 10.7% (2 mg), 16.4% (4 mg) and 17.7% (6 mg), compared to placebo (1.4%).
- 6 mg · ae_dc · press release
Permanent treatment discontinuation rates due to TEAEs were very low with 0.7% (1 participant, 2 mg), 0.7% (1 participant, 4 mg), 1.4% (2 participants, 6 mg) and 0% (placebo).
- 6 mg · nausea · abstract
Nausea 7 (4.9) 23 (16.2) 24 (17.0) 38 (27.0)
- 6 mg · vomiting · abstract
Vomiting 3 (2.1) 20 (14.1) 27 (19.1) 34 (24.1)
- 6 mg · sae · abstract
SAEs 8 (5.6) 2 (1.4) 7 (5.0) 6 (4.3)
- 6 mg · weight_eff · press release
Based on the hypothetical strategy estimand^I, participants taking HRS9531 achieved a mean weight loss of 11.2% (2 mg), 17.4% (4 mg) and 19.2% (6 mg), compared to placebo (1.4%).
Primary sources
- Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire text mirrored by santelog.com) [press release]. 2025-11-04. Available from: https://www.santelog.com/actualites-sante-nasdaq/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-phase-3
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract hrs9531_ow2025_slides.
- ClinicalTrials.gov NCT06396429
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS9531-301 (GEMINI-1, NCT06396429). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-301/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.